{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T19:01:22Z","timestamp":1772046082790,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T00:00:00Z","timestamp":1562457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pruritus is a leading cause of reduced health\u2010related quality of life (QoL) in atopic dermatitis (<jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>). Crisaborole ointment is a non\u2010steroidal phosphodiesterase 4 inhibitor for the treatment of mild\u2010to\u2010moderate <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>. In identical Phase 3 studies (<jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>02118766, <jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>02118792), crisaborole reduced disease and pruritus severity versus vehicle.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Quantify the relationship between pruritus and QoL using data from these studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients aged \u22652\u00a0years were randomly assigned 2\u00a0:\u00a01 to receive crisaborole:vehicle twice daily for 28\u00a0days. QoL was measured at baseline and day 29 using the Dermatology Life Quality Index (<jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content>; patients aged \u226516\u00a0years), the Children's Dermatology Life Quality Index (<jats:styled-content style=\"fixed-case\">CDLQI<\/jats:styled-content>; patients aged 2\u201315\u00a0years) and the Dermatitis Family Impact (<jats:styled-content style=\"fixed-case\">DFI<\/jats:styled-content>; caregivers of patients aged 2\u201317\u00a0years). Pruritus was measured using the Severity of Pruritus Scale (<jats:styled-content style=\"fixed-case\">SPS<\/jats:styled-content>), a 4\u2010point scale from 0 (\u2018no itching\u2019) to 3 (\u2018bothersome itching\/scratching that disturbs sleep\u2019), and captured morning and evening via electronic diary. Data from crisaborole and vehicle arms were pooled for this analysis. A repeated\u2010measures longitudinal model was used to estimate relationships between pruritus (<jats:styled-content style=\"fixed-case\">SPS<\/jats:styled-content>) and QoL (<jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> CDLQI<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">DFI<\/jats:styled-content> in separate analyses).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One thousand five hundred and twenty two patients received crisaborole or vehicle. A linearity assumption for the relationship between <jats:styled-content style=\"fixed-case\">SPS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content> (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>294), <jats:styled-content style=\"fixed-case\">CDLQI<\/jats:styled-content> (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>1200), and <jats:styled-content style=\"fixed-case\">DFI<\/jats:styled-content> (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>1293) was appropriate. For <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> SPS<\/jats:styled-content> score of 0 was associated with \u2018no negative effect on patient QoL\u2019; <jats:styled-content style=\"fixed-case\">SPS<\/jats:styled-content> score\u00a0of\u00a01 was associated with \u2018small effect on patient QoL\u2019; <jats:styled-content style=\"fixed-case\">SPS<\/jats:styled-content> score of 2 was associated with \u2018moderate effect on patient QoL\u2019; and <jats:styled-content style=\"fixed-case\">SPS<\/jats:styled-content> score of 3 was associated with \u2018very large effect on patient QoL\u2019. The pattern of relationships between <jats:styled-content style=\"fixed-case\">SPS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">CDLQI<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">DFI<\/jats:styled-content> was similar.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The relationships between <jats:styled-content style=\"fixed-case\">SPS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">DLQI<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> CDLQI<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">DFI<\/jats:styled-content> substantiate the significant link between pruritus and patient\/caregiver QoL in <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.15712","type":"journal-article","created":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T13:23:56Z","timestamp":1558963436000},"page":"1742-1746","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-7786","authenticated-orcid":false,"given":"S.","family":"St\u00e4nder","sequence":"first","affiliation":[{"name":"Center for Chronic Pruritus University Hospital M\u00fcnster M\u00fcnster Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Yosipovitch","sequence":"additional","affiliation":[{"name":"Miami Itch Center Miller School of Medicine University of Miami Miami FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.G.","family":"Bushmakin","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Groton CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Groton CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Luger","sequence":"additional","affiliation":[{"name":"University Hospital M\u00fcnster M\u00fcnster Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.L.","family":"Tom","sequence":"additional","affiliation":[{"name":"University of California San Diego CA USA"},{"name":"Rady Children's Hospital\u2013San Diego San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.C.","family":"Ports","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Groton CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Zielinski","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Collegeville PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Tallman","sequence":"additional","affiliation":[{"name":"Pfizer Inc. New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Tan","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Groton CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.A.","family":"Gerber","sequence":"additional","affiliation":[{"name":"Pfizer Inc. Groton CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,7,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra074081"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04710.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0582-z"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.04.019"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07185.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2005.22303.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.07.012"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2340\/00015555-0432","article-title":"Itch intensity evaluated in the German Atopic Dermatitis Intervention Study (GADIS): correlations with quality of life, coping behaviour and SCORAD severity in 823 children","volume":"88","author":"Weisshaar E","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04578.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.042"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb16953.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23621.x"},{"key":"e_1_2_6_15_1","first-page":"121","article-title":"Severity stratification of children's dermatology life quality index (CDLQI) scores","volume":"163","author":"Waters A","year":"2010","journal-title":"Br J Dermatol"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02034.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.05.046"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-018-0263-0"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/itx.0000000000000013"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1201\/b16139"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1824-7288-37-59"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.15712","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.15712","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.15712","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.15712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T05:58:43Z","timestamp":1694066323000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.15712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,7]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1111\/jdv.15712"],"URL":"https:\/\/doi.org\/10.1111\/jdv.15712","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,7]]},"assertion":[{"value":"2018-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}